<DOC>
	<DOCNO>NCT01309425</DOCNO>
	<brief_summary>The purpose study evaluate dose-proportionality pharmacokinetics tapentadol ( CG5503 ) healthy Japanese Korean adult male participant .</brief_summary>
	<brief_title>A Study Compare Dose-proportionality Tapentadol ( CG5503 ) Healthy Japanese Korean Male Volunteers</brief_title>
	<detailed_description>This single-dose , open-label , single-center , randomize , four-way crossover study , ie , participant investigator know identity drug , assign chance , like flip coin , participant may receive different intervention sequentially study . The study consist 4 treatment period . A single dose tapentadol ( CG5503 ) administer orally 240 mL water fast condition . All participant receive 1 follow 4 oral treatment period . Treatment A : One 25-mg tablet ( 25 mg ) tapentadol ( CG5503 ) Treatment B : One 50-mg tablet ( 50 mg ) tapentadol ( CG5503 ) Treatment C : One 100-mg tablet ( 100 mg ) tapentadol ( CG5503 ) Treatment D : Two 100-mg tablet ( 200 mg ) tapentadol ( CG5503 ) Each period separate 7 - 14 day .</detailed_description>
	<criteria>Healthy Japanese Korean male volunteer , inclusive Body mass index ( BMI ) 18.5 25 kg/mÂ² , inclusive , body weight less 50 kg Japanese volunteer must reside outside Japan 5 year , parent maternal paternal grandparent Japanese . Korean volunteer must reside outside Korea 5 year parent maternal paternal grandparent Korean . History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease History hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality History significant pulmonary disease , include bronchospastic respiratory disease History diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant could interfere interpretation study result Use prescription nonprescription medication ( include vitamin herbal supplement ) , except paracetamolacetaminophen , within 14 day first dose study drug schedule History , reason believe participant history drug alcohol abuse within past 5 year</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>tapentadol</keyword>
	<keyword>NUCYNTA</keyword>
	<keyword>CG5503</keyword>
	<keyword>R331333</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>